The majority of materials we rely on in our built environment come from chemicals derived from petroleum (petrochemicals), ...

IMUNON (IMNN) announced the presentation of new clinical data from the recently completed Phase 2 OVATION 2 Study of IMNN-001, its ...

Finally, the researchers describe a way to exploit ecDNA’s high rate of replication and transcription: a conflict between DNA ...

The ability to genetically engineer plants is largely thanks to a microscopic helper: a bacterium called Agrobacterium ...

Adapted from a news release by the Innovative Genomics Institute (IGI) at UC Berkeley.The ability to genetically engineer plants is largely thanks to ...

As previously announced, IMUNON plans to hold an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) in person to discuss the design for a Phase 3 pivotal study of IMNN-001 in ...

IMUNON will continue to leverage these modalities and to advance the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions, and to further strengthen IMUNON ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...